Loading...
Glaukos Corporation announced financial results for the first quarter ended March 31, 2022, with net sales of $67.7 million. The company updated its 2022 net sales guidance to $270 million to $275 million.
Net sales of $67.7 million in Q1 2022.
Glaucoma net sales of $51.5 million and Corneal Health net sales of $16.1 million in Q1 2022.
Gross margin of approximately 75% and non-GAAP gross margin of approximately 83% in Q1 2022.
Operating expenses of $40.8 million and non-GAAP operating expenses of $69.8 million in Q1 2022.
The company expects 2022 net sales to be in the range of $270 million to $275 million.